[Clinical analysis of the efficiency of the pathogenetic therapy for patients with parkinsonism]

The author has carried out (during 8-10 years) a long observation on 342 patients aged 42-73 years with Parkinson's disease. Pecularities of the action of a complex pathogenetic therapy on main symptoms of the disease as well as the frequency of adverse effects under the use of different classes of antiparkinsonian drugs have been analyzed. The drugs of the first choice of initial monotherapy were amantadin (39.7% of the patients), cholinergic antagonists (33.3% of the patients), MAO-B inhibitors (14.1% of the patients), antagonists of DA-receptors (9.0% of the patients) and on 3.9% of the patients have received levodopa-based drugs. Adverse events happened in 72.2% of cases with patients receiving levodopa-based drugs, in 49.9% of cases with patients receiving amantadin and in 47.1% of cases with patients receiving cholinergic antagonists.